« Back
Home /
CB1/2 agonist 4

CB1/2 agonist 4

Item no.	HY-150030-100mg
Manufacturer	MedChem Express
CASRN	2772949-38-7
Amount	100 mg
Quantity options	100 mg 1 ea
Category	Reagents & Chemicals Biochemicals
Type	Chemicals
Specific against	other
Citations	[1]Antonella Brizzi, et al. Synthetic bioactive olivetol-related amides: The influence of the phenolic group in cannabinoid receptor activity. Bioorg Med Chem. 2020 Jun 1;28(11):115513.
Smiles	O=C(NC1CC1)CCCCCCCOC2=CC(C(CCCCCC)(C)C)=CC(OC)=C2
ECLASS 10.1	32160000
ECLASS 11.0	32160000
UNSPSC	12000000
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Neuroscience-Neuromodulation
Manufacturer - Targets	Cannabinoid Receptor
Shipping Temperature	Room temperature
Molecular Weight	431.65
Product Description	CB1/2 agonist 4 is a full CB1 agonist and CB2 partial agonist with EC50 values of 15.09 nM and 1.16 nM, respectively. CB1/2 agonist 4 also has hCB1 and hCB2 receptor affinities with Ki values of 1.1 nM and 4.2 nM, respectively. CB1/2 agonist 4 has a significant antinociceptive activity, and also can activate cannabinoid and TRPV1 receptor with values of IC50 and EC50 is 0.8 μM and 0.12 μM, respectively[1].
Manufacturer - Research Area	Neurological Disease
Solubility	10 mM in DMSO
Manufacturer - Pathway	GPCR/G Protein; Neuronal Signaling
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 100 mg

available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question